The reverse side of the victory: Flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases

The development of angiogenesis inhibitors introduced a new era in the treatment of metastatic renal cell carcinoma (mRCC). By now, sunitinib and sorafenib both multiple tyrosine kinase inhibitors ...